The largest database of trusted experimental protocols

14 protocols using phosphatidylcholine

1

Docetaxel and Bicalutamide Solubility Enhancement

Check if the same lab product or an alternative is used in the 5 most similar protocols
Docetaxel (DTX, Mw = 807.9 g/mol, 99.4% purity) was obtained from Xingcheng Chempharm (Zhejiang, China) and bicalutamide (BIC, Mw = 430.3 g/mol, 99.7% purity) was obtained from Taizhou Creating Chemical (Taizhou, China). Bovine bile extract, Tween 80, dimethyl sulfoxide and Tris maleate salt were purchased from Sigma-Aldrich (St. Louis, MO, USA), phosphatidylcholine (99%) was purchased from Lipoid (Ludwigshafen, Germany), and sodium chloride (99.5%) was purchased from Fluka Chemie AG (Buchs, Switzerland). Phosphate buffered saline (PBS) and fasted state simulated intestinal fluid (FaSSIF) were purchased from Corning (Midland, MI, USA) and Biorelevant (London, UK), respectively. Ultrapure water (SG Water Purification System, Barsbuttel, Germany) was used for all experiments. All other chemicals and solvents were of analytical grade and were used without further purification.
+ Open protocol
+ Expand
2

Virosomal Formulations for Multi-Antigen Vaccines

Check if the same lab product or an alternative is used in the 5 most similar protocols
Four different virosomal preparations have been specifically designed for this study, three of them containing each of the individual antigens, and one containing all the three antigens together. Briefly, a solution containing 1 mg of inactivated Influenza virus A/H1N1/California was pelleted at 286 000g for 1 hour, dissolved in presence of 0.5 ml of PBS containing 0.1 M of Octaethyleneglycol mono (n-dodecyl) ether (OEG; Sigma Aldrich, MO, USA), and then mixed with 32 mg of phosphatidylcholine (Lipoid Ag, Steinhausen, Switzerland) dissolved in 1.5 ml of PBS-OEG 0.1 M. The mixture was centrifuged at 100 000g for 30 min and the supernatant containing Haemagglutinin and Neuraminidase was recovered. For the individual virosomal formulations, the obtained supernatant was then mixed with 2 mg of Leish-F3 (or Leish-F3+), or KMP11 or LJL143 in presence of detergent. Virosomes were then formed by detergent removal and sterile-filtered. The virosome particles containing the mixture of the three antigens were produced similarly, from 1 mg of starting influenza protein mixed with 1 mg of each antigen (Leish F3+, KMP11 and LJL143). Size determination and distribution of the particle population was performed using a Zetasizer Nano instrument (Malvern Instruments, Malvern, UK). Parasite derived and/or VD proteins content in virosome particle was determined by SDS-PAGE Coomassie Stained.
+ Open protocol
+ Expand
3

Virosome-based vaccine antigen preparation

Check if the same lab product or an alternative is used in the 5 most similar protocols
Virosomes containing each of the antigens individually were prepared, as previously described [26 (link)]. Briefly, a mixture of 1 mg of inactivated influenza virus A/H1N1/California and 32 mg of phosphatidylcholine (Lipoid Ag, Steinhausen, Switzerland) was centrifuged at 100,000× g for 30 min, and the supernatant, containing haemagglutinin and neuraminidase, was recovered. These influenza antigens were then used to produce VS that included the vaccine antigens (individually) by detergent removal. The VS were then sterile-filtered and their size distribution was determined using a Zetasizer Nano instrument (Malvern Instruments, Malvern, UK). The parasite-derived and/or virus-derived protein contents of the VS were checked by SDS-PAGE Coomassie staining.
+ Open protocol
+ Expand
4

Fructose Dehydrogenase Immobilization on Functionalized AuNPs

Check if the same lab product or an alternative is used in the 5 most similar protocols
d-(-)-Fructose, sodium acetate (NaAc), spherical gold nanoparticles (AuNSphs, d = 100 nm stabilized in citric acid), HAuCl4, hydrochloric acid (HCl), sodium hydroxide (NaOH), H2SO4, and sodium dodecyl sulfate (SDS) were purchased from Sigma-Aldrich (St. Louis, MO, USA). The phospholipids, 1,2-dimyristoyl-sn-glycero-3-phospho-rac-glycerol sodium salt (DMPG-Na), and phosphatidylcholine (PC) were kindly donated by LIPOID AG (Germany). d-Fructose dehydrogenase from Gluconobacter japonicus (FDH; EC 1.1.99.11) was purified from the culture supernatant of Gluconobacter japonicus NBRC 3260 obtained from the National Institute of Technology and Evaluation (Nishinomiya, Hyogo Pref., Japan), and solubilized in PBS buffer pH 6 (50~500 mM) containing 0.1 mM 2-mercaptoethanol and 0.1% v/v Triton X-100 (volumetric activity measured with potassium ferricyanide at pH 4.5 = 420 ± 30 U mL−1, specific activity = 250 ± 30 U mg−1, protein concentration = 1.7 ± 0.2 mg mL−1) [20 (link)]. All solutions were prepared using Milli-Q water (ρ = 18.2 MΩ cm at 25 °C; total organic compounds (TOC) < 10 μg L−1, Millipore, Molsheim, France).
+ Open protocol
+ Expand
5

Transfersomes and Emulsion Formulation

Check if the same lab product or an alternative is used in the 5 most similar protocols
Ceramide III (Evonik Nutrition & Care, Essen, Germany), α-Tocopherol (Merck Chemicals and life, Barcelona, Spain), phosphatidylcholine (Lipoid, Ludwigshafen, Germany), Tween 80 (Croda Iberica S.A., Barcelona, Spain), Retynil Palmitate and Ethanol Absolute (Scharlab S.L. Barcelona, Spain) and purified water (Inhouse) were used to formulate the transfersomes. Dissodium EDTA (Sucesores de Jose Escuder, S.L., Barcelona, Spain), PEG-6 stearate (and) Ceteth-20 (and) Steareth-20 (Gattefosse España, Madrid, Spain), Cetyl Sterayl alcohol (Basf, Barcelona, Spain), medium chain triglicerides (Oximed expres S.A., Barcelona, Spain) and Xanthan gum (Azelis españa S.A., Barcelona, Spain) were used to formulate the emulsion. Metanol (Scharlab S.L., Barcelona, Spain), Nile Red, Hoeschst, phosphate buffer saline, paraformaldehyde (Sigma Aldrich, Madrid, Spain), uranyl acetate, optimal cutting temperature compound (IESMAT S.A., Barcelona, Spain), were used to perform the different analyses.
+ Open protocol
+ Expand
6

Liposomal Formulation Preparation

Check if the same lab product or an alternative is used in the 5 most similar protocols
The CP used in the study was a generous gift from Hetero Drugs (Hyderabad, India); phosphatidyl choline was a gift from Lipoid GmbH (Ludwigshafen am Rhein, Germany); while cholesterol, ethanol, methanol, chloroform, and all other solvents of analytical reagent grade were purchased from SD Fine-Chem Limited (Mumbai, India).
+ Open protocol
+ Expand
7

Clodronate Liposome Encapsulation Protocol

Check if the same lab product or an alternative is used in the 5 most similar protocols
PBS and clodronate liposomes were prepared following the previous report (Van Rooijen and Sanders, 1994 (link)). Under the protection of argon, clodronate was encapsulated in liposomes that consisted of phosphatidylcholine (Lipoid, Germany) and cholesterol (Sigma–Aldrich).
+ Open protocol
+ Expand
8

Rapamycin-loaded Integrin-Targeted Micelles

Check if the same lab product or an alternative is used in the 5 most similar protocols
Phospholipid/polysorbate 80 micelle nanoparticles (NP) were prepared as a microfluidized suspension of 20% (v/v) combining polysorbate 80 (NOF America) with a 2.0% (w/v) commixture and 1.7% (w/v) glycerin in pH 6.5 carbonate buffer. The commixture included 2 mole% rapamycin, 0.15 mole% αvβ3-PEG2000-PE (Supplementary Information), and high-purity phosphatidylcholine (Lipoid). Rapamycin was excluded from commixture for targeted, drug-free nanoparticles. The lipid commixtures were combined with the polysorbate, buffer, and glycerin and homogenized at 20,000 psi for 4 minutes at 4°C with a microfluidics homogenizer (M110s or LV1, Microfluidics, Inc). Nanoparticles were sterile filtered and preserved under inert gas in sterile sealed vials until use. Dynamic light scattering (Zeta Plus, BrookHaven) showed nominal particle size of 23.9 nm, with polydispersity of 0.258 and an average electrophoretic zeta potential of −−1.61mv for αvβ3-RAPA-NPs, which were closely similar to αvβ3-CF-NP control.
+ Open protocol
+ Expand
9

Formulation and Characterization of Furosemide Delivery System

Check if the same lab product or an alternative is used in the 5 most similar protocols
PLLA granulate 2002D was obtained from Nature Works LLC (Blair, USA). Furosemide (˃98% purity) and taurocholic acid sodium salt hydrate (sodium taurocholate) were purchased from Sigma-Aldrich (St. Louis, MO, USA).
Eudragit® L100 was obtained from Evonik Industries (Darmstadt, Germany). phosphatidylcholine (Lipoid S PC, purity ≥ 98% phosphatidylcholine) was obtained from Lipoid AG (Ludwigshafen, Germany). Sodium azide, sodium chloride and potassium dihydrogen phosphate were acquired from Merck (Darmstadt, Germany). Ultra-purified water was obtained from an SG Ultra Clear water system (SG Water USA, LLC, Nashua, NH, USA) and was freshly produced in all cases. All other chemicals used were of analytical grade.
+ Open protocol
+ Expand
10

Therapeutic Mixed Micelle Preparation

Check if the same lab product or an alternative is used in the 5 most similar protocols
Preparation of CPT-PD was achieved via a one-step coupling of oxidized lipid PAzPC (1-palmitoyl-2-azelaoyl-sn-glycero-3-phosphocholine) with CPT (Supplementary methods). A VLA-4 antagonist based on the highly selective peptidomimetic, LLP2A (19 (link)), was synthesized and coupled to a polyethylene glycol–phosphatidyethanolamine anchor as detailed in Supplementary methods (Fig 1A, Suppl 1D-E). Therapeutic mixed micelles were prepared by microfluidization. The surfactant co-mixture of nanoparticles included phosphatidylcholine (Lipoid, Ludwigshafen, Germany) and 0.18 mol% of VLA4-PEG-PE. The peptidomimetic αvβ3-integrin homing ligand was a gift from Kereos, Inc. (St. Louis, MO) and incorporated into control micellar nanoparticles as previously described (21 (link)). For particle uptake assays, DiI (1 mol%, Thermo Fisher Scientific Inc, Waltham, MA) was incorporated. V-CP included 4 mol% of CPT-PD, and was replaced in “No-Drug” (ND) nanoparticles by phosphatidylcholine. Dynamic light scattering was performed with ZetaPlus (Brookhaven Instruments Corporation) on every batch: particle size (average 18.2 ± 3.0), polydispersity (0.24), and electrophoretic zeta potential (−3.1 mV). Data from several batches V-NP illustrated high batch-to-batch reproducibility and long-term shelf-life stability (~1 year at 4°C) (Suppl Fig 1F).
+ Open protocol
+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required

Sign up now

Revolutionizing how scientists
search and build protocols!